Related Experiment Videos
Clinical trials for severe sepsis. Past failures, and future hopes
Abstract:
Recent clinical trials with experimental immunotherapeutic agents for severe sepsis and septic shock have been largely unsuccessful despite seemingly convincing preclinical evidence of significant benefit of these antisepsis therapies. This article reviews basic therapeutic rationale, preclinical evaluation, and clinical trial design of past clinical trials of innovative sepsis treatments. Lessons learned from past failures should provide insights into the design and implementation of successful clinical trials for new anti-sepsis agents in the future.
Insights
Experimental immunotherapies for severe sepsis and septic shock have failed in clinical trials, despite promising preclinical data. Reviewing past trials offers crucial lessons for designing future successful sepsis treatments.
Area of Science:
- Critical care medicine
- Immunology
- Clinical trial design
Background:
- Severe sepsis and septic shock remain leading causes of mortality worldwide.
- Despite extensive research, immunotherapeutic agents have shown limited success in clinical settings.
- Preclinical studies often suggest significant benefits that do not translate to human trials.
Purpose of the Study:
- To review the therapeutic rationale behind immunotherapies for sepsis.
- To analyze preclinical evaluation methods for sepsis treatments.
- To examine clinical trial designs of past innovative sepsis therapies.
Main Methods:
- Literature review of published clinical trials for severe sepsis and septic shock.
- Analysis of preclinical data and therapeutic strategies for immunotherapies.
- Evaluation of clinical trial designs, including patient selection and outcome measures.
Main Results:
- Numerous immunotherapeutic agents have failed to demonstrate efficacy in severe sepsis and septic shock.
- Discrepancies between preclinical promise and clinical outcomes are common.
- Past clinical trial designs may have contributed to the observed failures.
Conclusions:
- Past failures highlight critical gaps in our understanding of sepsis pathophysiology and treatment response.
- Lessons learned from previous immunotherapeutic trials are essential for future drug development.
- Improved preclinical models and refined clinical trial designs are necessary for advancing sepsis treatment.